Ge. Hanks et al., Dose selection for prostate cancer patients based on dose comparison and dose response studies, INT J RAD O, 46(4), 2000, pp. 823-832
Citations number
29
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Purpose: To better define the appropriate dose for individual prostate canc
er patients treated with three-dimensional conformal radiation therapy (3D
CRT).
Methods and Materials: Six hundred eighteen patients treated with 3D CRT be
tween 4/89 and 4/97 with a median follow-up of 53 months are the subject of
this study. The bNED outcomes were assessed by the American Society for Th
erapeutic Radiology and Oncology (ASTRO) definition. The patients were grou
ped into three groups by prostate-specific antigen (PSA) level (<10 ng/ml,
10-19.9 ng/ml, and 20+ ng/ml) and further subgrouped into six subgroups by
favorable (T1, 2A and Gleason score less than or equal to 6 and no perineur
al invasion) and unfavorable characteristics (one or more of T2B, T3, Gleas
on 7-10, perineural invasion). Dose comparisons for bNED studies were made
for each of the six subgroups by dividing patients at 76 Gy for all subgrou
ps except the favorable <10 ng/ml subgroup, which was divided at 72.5 Gy. F
ive-year bNED rates were compared for the median dose of each dose comparis
on subgroup. Dose response functions were plotted based on 5-year bNED rate
s for the six patient groupings, with the data from each of the six subgrou
ps divided into three dose groups. The 5-year bNED rate was also estimated
using the dose response function and compares 73 Gy with 78 Gy.
Results: Dose comparisons show a significant difference in 5-year bNED rate
s for three of the six subgroups but not for the favorable <10 ng/ml, the f
avorable 10-19.9 ng/ml, or the unfavorable greater than or equal to 20 ng/m
l subgroups. The significant differences ranged from 22% to 40% improvement
in 5-year bNED with higher dose. Dose response functions show significant
differences in 5-year bNED rates comparing 73 Gy and 78 Gy for four of the
six subgroups. Again, no difference was observed for the favorable <10 ng/m
l group or the unfavorable greater than or equal to 20 ng/ml group. The sig
nificant differences observed in 5-year bNED ranged from 15% to 43%.
Conclusions: Dose response varies by patient subgroup, and appropriate dose
can be estimated for up to six subdivisions of prostate cancer patients. T
he appropriate use of high dose with 3D CRT results in 5-year cure rates th
at equal or exceed other treatments. The national practice must be upgraded
to allow the safe administration of 75-80 Gy with 3D CRT. (C) 2000 Elsevie
r Science Inc.